Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
Abstract The spiroindolones, a new class of antimalarial medicines discovered Pads in a cellular screen, are rendered less active by mutations in a parasite P-type ATPase, PfATP4.We show here that S.cerevisiae also acquires mutations in a gene encoding a P-type ATPase (ScPMA1) after exposure to spiroindolones and that these mutations are sufficient